BR9712951A - Processo para piridinas substituìdas - Google Patents
Processo para piridinas substituìdasInfo
- Publication number
- BR9712951A BR9712951A BR9712951-8A BR9712951A BR9712951A BR 9712951 A BR9712951 A BR 9712951A BR 9712951 A BR9712951 A BR 9712951A BR 9712951 A BR9712951 A BR 9712951A
- Authority
- BR
- Brazil
- Prior art keywords
- amino
- substituted pyridines
- nitro
- processes
- formula
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 150000003222 pyridines Chemical class 0.000 title abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 239000000048 adrenergic agonist Substances 0.000 abstract 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- -1 nitro, amino Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Patente de Invenção:<B>"PROCESSO PARA PIRIDINAS SUBSTITUìDAS"<D>. Esta invenção refere-se a processos para a preparação de compostos da fórmula (I) que são <225> agonistas receptores adrenérgicos, e a processos para a preparácão de certos intermediários da fórmula (IIA) em que R^ 1^ é nitro, amino ou amino protegido; R^ 2^ é H, flúor, cloro, CF~ 3~, nitro, alquila C~ 1~ -C~ 4~ alcóxi C~ 1~- C~ 4~ , amino ou amino protegido; e X^ 1^ é OH ou um grupo de saída adequado, usados naquele processo. A invenção refere-se a novos compostos das fórmulas (II).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3088096P | 1996-11-14 | 1996-11-14 | |
| PCT/IB1997/001367 WO1998021184A1 (en) | 1996-11-14 | 1997-11-03 | Process for substituted pyridines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9712951A true BR9712951A (pt) | 1999-12-07 |
Family
ID=21856496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9712951-8A BR9712951A (pt) | 1996-11-14 | 1997-11-03 | Processo para piridinas substituìdas |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US6291489B1 (pt) |
| EP (1) | EP0938476B1 (pt) |
| JP (1) | JP3510635B2 (pt) |
| KR (1) | KR20000053314A (pt) |
| CN (1) | CN1237160A (pt) |
| AP (1) | AP805A (pt) |
| AR (1) | AR010584A1 (pt) |
| AT (1) | ATE319687T1 (pt) |
| AU (1) | AU4634697A (pt) |
| BG (1) | BG103393A (pt) |
| BR (1) | BR9712951A (pt) |
| CA (1) | CA2270386C (pt) |
| CO (1) | CO4930261A1 (pt) |
| DE (1) | DE69735433D1 (pt) |
| EA (1) | EA199900375A1 (pt) |
| GT (1) | GT199700118A (pt) |
| HR (1) | HRP970612A2 (pt) |
| ID (1) | ID18898A (pt) |
| IL (1) | IL129688A0 (pt) |
| IS (1) | IS5029A (pt) |
| MA (1) | MA24401A1 (pt) |
| MY (1) | MY132507A (pt) |
| NO (1) | NO992296L (pt) |
| OA (1) | OA11044A (pt) |
| PA (1) | PA8441401A1 (pt) |
| PE (1) | PE10299A1 (pt) |
| TN (1) | TNSN97172A1 (pt) |
| TR (1) | TR199901063T2 (pt) |
| UY (1) | UY24774A1 (pt) |
| WO (1) | WO1998021184A1 (pt) |
| YU (1) | YU22099A (pt) |
| ZA (1) | ZA9710186B (pt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010042518A (ko) * | 1998-04-08 | 2001-05-25 | 한스 루돌프 하우스, 헨리테 브룬너, 베아트리체 귄터 | 신규 제초제 |
| US6090942A (en) * | 1998-10-15 | 2000-07-18 | Pfizer Inc. | Process and intermediates for a β3 -adrenergic receptor agonist |
| KR20010102198A (ko) | 1999-02-16 | 2001-11-15 | 후루타 타케시 | 치환 아세틸피리딘 유도체 및 그를 이용하는 광학활성 β3작용제 중간체의 제조 방법 |
| US6455734B1 (en) * | 2000-08-09 | 2002-09-24 | Magnesium Diagnostics, Inc. | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| EP1078924B1 (en) * | 1999-07-23 | 2004-10-20 | Pfizer Products Inc. | Intermediates and a process for producing beta-adrenergic receptor agonists |
| US20040265991A1 (en) * | 2001-10-17 | 2004-12-30 | Naoaki Taoka | Process for preparation of (s)-alpha-halomethylpyridine-methanol derivatives |
| WO2003072547A1 (en) | 2002-02-27 | 2003-09-04 | Pfizer Products Inc. | PROCESSES AND INTERMEDIATES USEFUL IN PREPARING β3-ADRENERGIC RECEPTOR AGONISTS |
| US6864268B2 (en) | 2002-02-27 | 2005-03-08 | Pfizer Inc. | β3 adrenergic receptor agonists |
| AU2003209527A1 (en) | 2002-02-27 | 2003-09-09 | Pfizer Products Inc. | Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol |
| EP1424079A1 (en) * | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine |
| BRPI0410237A (pt) | 2003-05-09 | 2006-05-09 | Hoffmann La Roche | metil indóis e metil pirrolopiridinas como agonistas adrenérgicos alfa-1 |
| US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| US8399666B2 (en) | 2005-11-04 | 2013-03-19 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| GB2431927B (en) | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
| BRPI0912267A2 (pt) | 2008-05-23 | 2015-10-13 | Amira Pharmaceuticals Inc | sal farmaceuticamente aceitável, composição farmacêutica, artigo de fabricação, métodos para tratar asma, rinite alérgica, doença, lesões gástricas e dor, métodos para prevenir broncoconstrição e rinite alérgica, uso de um sal farmaceuticamente aceitável, e, processo para a preparação de um sal farmaceuticamente aceitável. |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4358455A (en) | 1980-12-23 | 1982-11-09 | Merck & Co., Inc. | Aralkylamindethanol heterocyclic compounds |
| US5019578A (en) | 1987-11-27 | 1991-05-28 | Merck & Co., Inc. | β-adrenergic agonists |
| KR960703120A (ko) | 1993-06-14 | 1996-06-19 | 알렌 제이. 스피겔 | 당뇨 및 비만 치료제로서의 2차아민(secondary amines as antidiabetic and antiobesity agents) |
| IL113410A (en) | 1994-04-26 | 1999-11-30 | Merck & Co Inc | Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them |
| EP0828712A1 (en) * | 1995-05-10 | 1998-03-18 | Pfizer Inc. | Beta-adrenergic agonists |
| JPH11504649A (ja) * | 1995-05-10 | 1999-04-27 | ファイザー・インコーポレーテッド | β−アドレナリン作働性アゴニスト |
-
1997
- 1997-11-03 TR TR1999/01063T patent/TR199901063T2/xx unknown
- 1997-11-03 DE DE69735433T patent/DE69735433D1/de not_active Expired - Lifetime
- 1997-11-03 YU YU22099A patent/YU22099A/sh unknown
- 1997-11-03 EA EA199900375A patent/EA199900375A1/ru unknown
- 1997-11-03 BR BR9712951-8A patent/BR9712951A/pt not_active Application Discontinuation
- 1997-11-03 JP JP52233298A patent/JP3510635B2/ja not_active Expired - Fee Related
- 1997-11-03 AT AT97945047T patent/ATE319687T1/de not_active IP Right Cessation
- 1997-11-03 EP EP97945047A patent/EP0938476B1/en not_active Expired - Lifetime
- 1997-11-03 AU AU46346/97A patent/AU4634697A/en not_active Abandoned
- 1997-11-03 KR KR1019990704312A patent/KR20000053314A/ko active IP Right Grant
- 1997-11-03 IL IL12968897A patent/IL129688A0/xx unknown
- 1997-11-03 WO PCT/IB1997/001367 patent/WO1998021184A1/en active IP Right Grant
- 1997-11-03 CA CA002270386A patent/CA2270386C/en not_active Expired - Fee Related
- 1997-11-03 US US09/297,694 patent/US6291489B1/en not_active Expired - Fee Related
- 1997-11-03 CN CN97199663A patent/CN1237160A/zh active Pending
- 1997-11-11 GT GT199700118A patent/GT199700118A/es unknown
- 1997-11-11 MA MA24864A patent/MA24401A1/fr unknown
- 1997-11-11 PE PE1997001004A patent/PE10299A1/es not_active Application Discontinuation
- 1997-11-12 ZA ZA9710186A patent/ZA9710186B/xx unknown
- 1997-11-12 UY UY24774A patent/UY24774A1/es unknown
- 1997-11-12 TN TNTNSN97172A patent/TNSN97172A1/fr unknown
- 1997-11-12 MY MYPI97005396A patent/MY132507A/en unknown
- 1997-11-12 AR ARP970105279A patent/AR010584A1/es not_active Application Discontinuation
- 1997-11-12 PA PA19978441401A patent/PA8441401A1/es unknown
- 1997-11-13 ID IDP973662A patent/ID18898A/id unknown
- 1997-11-13 AP APAP/P/1997/001147A patent/AP805A/en active
- 1997-11-13 HR HR60/030,880A patent/HRP970612A2/hr not_active Application Discontinuation
- 1997-11-13 CO CO97066763A patent/CO4930261A1/es unknown
-
1999
- 1999-04-16 IS IS5029A patent/IS5029A/is unknown
- 1999-05-07 OA OA9900096A patent/OA11044A/en unknown
- 1999-05-11 BG BG103393A patent/BG103393A/xx unknown
- 1999-05-12 NO NO992296A patent/NO992296L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9712951A (pt) | Processo para piridinas substituìdas | |
| BR0212733A (pt) | Composto, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio afetivo | |
| BR9714155A (pt) | Prevenção da perda e reposição da massa óssea por certos agonistas de prostaglandina. | |
| BR9907300A (pt) | Inibidores do fator xa oxoaza-heterociclila substituìdos | |
| BR9915403A (pt) | Antagonistas receptores iii de 4-aroil-piperidin-ccr-3 | |
| UY24949A1 (es) | Compuestos calcilíticos | |
| BR0307351A (pt) | Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto | |
| HUP0203509A2 (hu) | Triciklusos pirazolkarbonsav-származékok, a vegyületek előállítása és a vegyületeket tartalmazó gyógyászati készítmények | |
| BR9814300A (pt) | Método de preparação de óxidos de tetraidrobenzotiepina enanciomericamente enriquecidos | |
| BR9813989A (pt) | Composto, processo para prepará-lo, uso do mesmo, composição farmacêutica, e, processo para o tratamento de um paciente sofrendo de uma condição | |
| BR9915381A (pt) | Uso de um composto, e, composto | |
| BR9810829A (pt) | Composto, processo para preparar o mesmo, composição, uso de um composto ou um sal farmaceuticamente aceitável do mesmo ou uma composição, e, processo de tratamento de uma condição | |
| ID18883A (id) | Pesaing 5-ht 1f | |
| BR9911137A (pt) | Processo para tratamento de correntes de fluido | |
| BR9811301A (pt) | Processo para preparar brometos de benzila substituìdos | |
| BR0208992A (pt) | Processo para a preparação de indenos 1,3-substituìdos e compostos azapolicìclicos fundidos com arila | |
| BR0207832A (pt) | Compostos de carbamato para uso na prevenção ou tratamento de distúrbio bipolar | |
| BR9909555A (pt) | Herbicidas | |
| BR9812892A (pt) | 2 4-diamino-1,3,5-triazinas substituìdas e seu emprego como herbicidas | |
| FI952094A0 (fi) | Ihmisen serotoniinireseptoria (5-HT4B)koodaava DNA ja sen käyttö | |
| BR9807988A (pt) | Processo para a preparação de um composto, e, composto. | |
| BR0207830A (pt) | Compostos de carbamato para uso em prevenir ou tratar distúrbios de ansiedade | |
| BR0316070A (pt) | Composto, composição farmacêutica, uso de um composto e, método para modular mchr | |
| BR0211425A (pt) | Método para a preparação de compostos, e, uso de uma composição | |
| BR9807190A (pt) | Processo para hidrogenação de um composto no grupo das iminas ou enaminas i a uma amina ii na presença de uma nitrila iii, e, uso de catalisadores iv |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |